Ximena Oyarzún-González

Ximena Oyarzún-González

Auto-generated profile, based on publicly available information

Ximena Oyarzún-González

Ohio State Univ, Coll Pharm, Div Outcomes & Translat Sci, Riffe Bldg, Room 400, 496 W 12th Ave, Columbus, OH 43210 USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2015 in Journal of the American Geriatrics Society
Verified
Journal Article
Open access
PDF file
XOXimena A. Oyarzun‐Gonzalez
Ximena A. Oyarzun‐Gonzalez
KTKira C Taylor
Kira C Taylor
SMSteven R. Myers
Steven R. Myers
SMSusan B. Muldoon
Susan B. Muldoon
RBRichard N. Baumgartner
Richard N. Baumgartner

10 February 2020 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
XOXimena Oyarzún‐González
Ximena Oyarzún‐González
CFCatterina Ferreccio
Catterina Ferreccio
EAErin L. Abner
Erin L. Abner
CVClaudio Vargas
Claudio Vargas
AHAndrea Huidobro
Andrea Huidobro
PTPablo Toro
Pablo Toro

1 September 2023 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
XOXimena Oyarzún-González
Ximena Oyarzún-González
EAErin L. Abner
Erin L. Abner
PTPablo Toro
Pablo Toro
CFCatterina Ferreccio
Catterina Ferreccio
Background: Subjective memory complaints (SMC) are commonly studied in older adults and have been identified as potentially prodromal to dementia and Alzheimer’s disease. Studies among younger adults from South America are lacking. Objective: To estimate the prevalence of SMC and the factors associated with it among Maule Cohort (MAUCO) participants. Methods: We performed a cross-sectional analysis to estimate the prevalence of SMC and investigated its associated factors from MAUCO baseline data (N = 6,687). Within groups defined by age (38–59, 60–74) and global cognition (Mini-Mental State Examination: ≥26, 25-22, ≤21), multinomial logistic regression models evaluated risk factors for SMC (Yes, Sometimes, No). Results: Overall, SMC prevalence was 16.4%; 15.9% (95% CI 14.9–16.9%) among younger and 17.6% (15.8–19.4%) among older participants. Female sex, comorbidities, and bad/fair self-reported health status (SRHS) were generally associated with higher odds of SMC. Conclusion: Overall prevalence of SMC was 16%. Different factors were associated with the odds of SMC depending on age and global cognitive status. Future SMC studies should include sex-specific assessments, evaluate SRHS as a moderator of SMC reporting, and the influence of the SARS-CoV-2 pandemic on SMC reporting.

31 May 2024 in Journal of the American Pharmacists Association
Verified
Journal Article
Open access
XOXimena Oyarzún-González
Ximena Oyarzún-González
EAErin L. Abner
Erin L. Abner
PFPatricia Freeman
Patricia Freeman
AKAnna Kucharska-Newton
Anna Kucharska-Newton
DFDavid Fardo
David Fardo
DMDaniela C. Moga
Daniela C. Moga
Background: The Medicare Medication Therapy Management (MTM) program has been available to eligible Medicare Part D beneficiaries since 2006, but research regarding program utilization and characterization is limited. Objective: To describe enrollee and MTM program characteristics in a national sample of Medicare fee-for-service (FFS) beneficiaries (2013 to 2016). Methods: Using a 5% random sample of Medicare FFS beneficiaries, we conducted a descriptive time series analysis to examine annual MTM enrollment and describe the type of MTM criteria at enrollment (Center for Medicare and Medicaid Services [CMS] vs. expanded). We investigated the offer of Comprehensive Medication Review (CMR) along with CMR receipt status, and delivery characteristics, as well as frequencies of Target Medication Reviews (TMRs). Result: Beneficiaries who met CMS enrollment criteria, compared to those eligible under expanded criteria, were significantly older, more likely to be of white race, more likely to be female, and had a significantly higher number of comorbidities. Of those meeting CMS criteria, the proportion receiving TMR increased from 95% in 2013% to 98.1% in 2016, and over 97% were offered a CMR. Although the proportion of beneficiaries offered a CMR was stable over the study period, the proportion who received a CMR increased from 17% in 2013% to 35.4% in 2016. Telephone CMR delivery was the most common method used (87.8% to 89.1% of CMRs over the study period). Over 95% of the CMRs were delivered by a pharmacist. Conclusion: During the years 2013 to 2016, enrollment in the MTM program increased, as did the proportion of enrollees receiving TMRs and CMRs. However, uptake remained low and the main factors driving participation remain unclear. Significant differences in demographic characteristics between beneficiaries enrolled under the CMS MTM enrollment criteria and the expanded criteria suggest the need to further investigate the optimal provision of such programs. (c) 2024 American Pharmacists Association (R). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).